NAD recommends Promensil claims changes
This article was originally published in The Tan Sheet
Executive Summary
Natrol's advertising for Promensil red clover dietary supplement for relief of menopause symptoms "overstates the results" of research used to back its claims and the firm should modify them accordingly, the National Advertising Division of the Council of Better Business Bureaus states Sept. 18. NAD reviewed claims including, "Why Promensil ... 22 clinical studies can't be wrong," and "Clinically Proven and Doctor Recommended." The group examined Natrol's research and found conflicting efficacy research and deficiencies in the study data provided by the Chatsworth, Calif.-based firm. However, Natrol provided a reasonable basis to make certain limited claims that Promensil can help relieve the frequency and/or severity of hot flashes, increase testosterone to alleviate certain mood swings and promote breast and heart health, NAD says. The CBBB group recommends Natrol discontinue the use of "Clinically Proven" phrase due to insufficient evidence and modify the "Doctor Recommended" claims to clearly disclose that physicians from Australia and Canada were used in the product's research. The NAD recommendations come after the Center for Science in the Public Interest expressed its concerns with the supplement's ads and labels claims calling for federal intervention (1"The Tan Sheet" Sept. 17, 2007, In Brief)...